CD274 and triple-negative breast carcinoma: Currently from the PDL-1 inhibitors, only pembrolizumab received one positive decision for PDL with an indication of ABC at the end of 2022, but both pembrolizumab and atezolizumab are included in the pharmaco-therapeutic guidelines for triple-negative breast cancer.